One canonical Semaglutide entity page for both MedCore research presentations, combining verified compound identity, regulatory context, strength-specific product information and authoritative sources.
Semaglutide is a 31-amino-acid polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist. PubChem lists it as CID 56843331 with molecular formula C187H291N45O59 and molecular weight of approximately 4114 g/mol.1
Semaglutide is also the active substance in authorized prescription medicines. That fact describes the compound and specific authorized medicines; it does not confer the same regulatory status on the MedCore research presentations shown on this page.
For a trustworthy research profile, the approved-drug evidence and the status of a separate research presentation must never be blended together.
EMA identifies semaglutide as the active substance in authorized medicines including Ozempic and Wegovy, each with its own authorized indications, formulation and product information.23
FDA states that unapproved GLP-1 products do not undergo its premarket review for safety, effectiveness and quality. FDA also warns that semaglutide salt forms such as semaglutide sodium or acetate are different active ingredients from the semaglutide used in approved drugs.4
MedCore Semaglutide 10 mg and 20 mg are presented on this website as research-information products. This page does not describe them as Ozempic, Wegovy, Rybelsus, generic equivalents or FDA/EMA-authorized medicines.
Both strengths remain on one canonical compound page so shared research context is not duplicated across near-identical URLs.
A distinct MedCore strength presentation within the canonical Semaglutide research profile.
A separate 20 mg MedCore presentation represented as a variant on this same Semaglutide entity page.
Semaglutide has extensive clinical and regulatory literature, but an SEO-strong page should not use that literature to imply that an unrelated research presentation has inherited the approvals, dosing instructions, safety profile or efficacy claims of a specific authorized medicine.
The MedCore page therefore separates three layers: compound identity, regulatory evidence for named approved medicines, and MedCore product-presentation information.
Compound entityPubChem identity and scientific classification.
Authorized-medicine contextEMA and FDA information about specific reviewed products.
MedCore presentation10 mg and 20 mg research product information only.
Product documentation should answer product-specific questions without borrowing claims from authorized medicines or scientific studies that do not test the MedCore presentation itself.
Strength-specific documentation preview for the MedCore Semaglutide research presentation.
These images are presented as sample product documentation and should not be interpreted as independently verified analytical certification. Product identity, batch data and analytical claims should be checked against original laboratory records.
Concise answers that keep compound facts, regulatory status and MedCore product information distinct.
Compound and regulatory statements are linked to scientific databases and regulators so the page can be reviewed independently. Last reviewed 2 September 2026.
Compound identity, molecular formula, molecular weight and classification.
Open PubChem source ↗EU regulatory information for the authorized medicine containing semaglutide.
Open EMA source ↗EU regulatory information for the authorized medicine containing semaglutide.
Open EMA source ↗FDA guidance on unapproved GLP-1 products and semaglutide salt forms.
Open FDA source ↗Review the documentation framework or contact MedCore for product-specific information.
